Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial
J. Ramsdell, J. D. Edelson, C. Compton, C. Vleisides, O. Amit, S. Kelsen, M. Strek, S. I. Rennard, S. Chodosh, N. Schachter (San Diego, Collegeville, Philadelphia, Chicago, Omaha, Boston, New York, United States Of America; Harlow, United Kingdom)
Source: Annual Congress 2001 - Respiratory structure and function in COPD
Session: Respiratory structure and function in COPD
Session type: Thematic Poster Session
Number: 673
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Ramsdell, J. D. Edelson, C. Compton, C. Vleisides, O. Amit, S. Kelsen, M. Strek, S. I. Rennard, S. Chodosh, N. Schachter (San Diego, Collegeville, Philadelphia, Chicago, Omaha, Boston, New York, United States Of America; Harlow, United Kingdom). Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial. Eur Respir J 2001; 16: Suppl. 31, 673
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Effect of phosphodiesterase 4B inhibitor GSK256066 on leukocyte/endothelium interactions from chronic obstructive pulmonary disease: an in vitro study. Source: International Congress 2017 – Management of COPD Year: 2017
Effect of phosphodiesterase 5 inhibitor in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Treatment of COPD Year: 2009
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2 -agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006
The proton pump inhibitor reduces the frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2009 - Treatment of COPD Year: 2009
Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Physiological effects of roflumilast at rest and during exercise in COPD Source: Eur Respir J 2012; 39: 1104-1112 Year: 2012
Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors Source: Eur Respir Rev 2007; 16: 105-112 Year: 2007
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002
Effects of phosphodiesterase type 5 inhibitor on pulmonary hemodynamics in the patients with high altitude pulmonary hypertension (results of 12 week randomized, blind, placebo-controlled study) Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005
Long-term health status in patients with poorly reversible chronic obstructive pulmonary disease (COPD) treated with cilomilast Source: Eur Respir J 2004; 24: Suppl. 48, 540s Year: 2004